



BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2021 (PART 2)

24–26 March 2021 Virtual event



RCR CPD accredited

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2021 (PART 2)

This is a virtual inaugural meeting for the BIR bringing together national and international experts sharing experiences and expertise in a very wide range of aspects for today's cutting-edge radiotherapy and oncology. The latest techniques, technologies, methods and issues will be discussed in this comprehensive meeting taking place over two days. Opportunities aplenty for networking with fellow professionals and discussing the latest offerings from manufacturers.

Who should attend?

This event will appeal to anyone working within radiotherapy and oncology including clinical oncologists, radiographers, physicists, service managers, Linac and IT engineers, dosimetrists, manufacturers and department heads.

Five reasons to attend

- 1. Enhance your knowledge
- 2. Hear expert opinion and share your own
- 3. Refresh your understanding
- 4. Share your own research
- 5. Network with colleagues, peers and industry representatives

CPD credits

The full event is worth up to 7 CPD credits in total: Day 1 = 3 CPD credits Day 2 = 3 CPD credits Day 3 = 2 CPD credits

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2021 (PART 2)

ePosters and proffered video clips

There will be electronic posters and video clips available in an online format, which can be viewed anytime from a computer, laptop or mobile device.



BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2021 WELCOMES ITS INDUSTRY PARTNERS

Platinum Sponsors



Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients' lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/



Bayer's Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www. radiology.bayer.co.uk



GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.



Siemens Healthineers is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. For more information and latest product line visit www.siemenshealthineers.co.uk

PHILIPS

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people's lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people's health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare

Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter. A pioneer in precision radiation medicine, Elekta develops and supports a range of advanced linear accelerators (linacs) that enable physicians to deliver precise, rapid and patient-specific radiotherapy for individuals with cancer. Elekta's line of high definition digital accelerators includes the latest generation Versa HD[™] – a system designed to treat a spectrum of tumours throughout the body using both conventional and highly sophisticated techniques - as well as the clinically-proven and widely used Elekta Synergy[®] and Elekta Infinity[™] linacs. MOSAIQ[®] Plaza is a comprehensive suite of digital tools that works seamlessly with Elekta radiotherapy systems to provide the foundation for intelligence-driven, value-based healthcare. MOSAIQ Plaza's smart data centre connects healthcare professionals to patients through every step of their journey to ensure efficient, standardized daily practice. Bringing people and information together, MOSAIQ Plaza allows departments to continuously improve their processes, reduce costs and touch more patients' lives.



ADVANCING CANCER TREATMENT

RaySearch is a committed pioneer of oncology software. Since 2000, we have worked in close cooperation with leading cancer centers to improve life and outcomes for patients. We develop all our products from the ground up and continuously revise every aspect, from algorithms to user interface designs. Medical science never stands still, and neither does RaySearch—our relentless drive to do things better leads us to ever-higher performance, accuracy, safety and usability. And this is just the beginning.

We believe software is the driving force for innovation in oncology today. Our systems use groundbreaking automation and machine learning to create new possibilities. RayCare[®]*, the next-generation oncology information system, will enable one workflow for all the oncology disciplines, ensuring fluid coordination of tasks and optimal use of resources. RayStation[®] harmonizes treatment planning, providing one point of control for all planning needs—any equipment, any scale.

* Subject to regulatory clearance in some markets.



Sun Nuclear provides innovative solutions for Radiation Therapy, Diagnostic Imaging and Patient Alignment. Our mission is to enable healthier lives by improving the detection and treatment of cancer. More than 5,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, we aim to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety.

varian

Varian is the world's leading manufacturer of integrated systems for treating cancer and other conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. Along with making an industry-leading treatment planning software for radiation treatments, Varian also develops informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.



Xiel is a specialist distributor of medical technologies in the UK and Ireland. We work with global leading solution providers including Sun Nuclear Corporation, CIRS Inc, CIVCO, Cablon Medical, Adaptiiv, Eckert and Ziegler and Rotop, to continuously improve efficiency and quality for all our customers.



MVision AI is a pioneering SaaS provider for radiotherapy treatment planning. Our AI-powered segmentation tool helps to standardize and automate contouring, including lymph nodes, to streamline workflow in radiotherapy. Our deep learning model produces consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time.

THE DOSIMETRY COMPANY

PTW designs, develops, manufactures and distributes high quality dosimetry and quality control equipment mainly for use
Y in the medical field, especially in radiation therapy, diagnostic radiology and nuclear medicine. We have a global network of subsidiaries including here in the UK and ROI. Our products are well known throughout the world and are recognized for their workmanship and high level of quality.



At Rosemont our mission is to improve the health, quality of life and wellbeing of vulnerable patients through the development, manufacture and supply of high-quality prescription oral liquid medicines. Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them.



At Terumo Interventional Systems, we constantly work to refine and perfect our products so that physicians can do more. Our QuiremSpheres (Selective Internal Radiation) Holmium Platform delivers a first in SIRT: a comprehensive end-to-end platform for treating unresectable liver tumours.

LADMSQ200116

MOSAIQ[®] Plaza

Connecting you to every moment of a patient's journey

MOSAIQ[®] Plaza transforms cancer care by personalizing every patient's treatment pathway. This integrated suite of digital tools ensures you achieve the highest quality decision-making while delivering value-based care—continuously adapting and optimizing based upon each unique individual patient journey.

Focus where it matters.

elekta.com/mosaiqplaza

Elekta

:06

1



IT'S PERSONAL

Oncology Treatment planning technology is evolving to meet the needs of our growing world population. We've developed machine learning tools* capable of transforming valuable real-time information into predictive and consistent organ segmentation, plan generation and optimization. Almost 10 million people die from cancer annually and treatment planning with machine learning is our latest contribution to the fight. For us, it's personal.

*Subject to regulatory clearance in some markets.

ADVANCING CANCER TREATMENT



Welcome to a new world of CT simulation



We've transformed CT technology to create meaningful, large-bore RT imaging solutions that unlock key innovations for your field. And by integrating dedicated RT hardware and AI-supported software, they come ready-equipped to enable you to fight cancer on a new level.

SOMATOM go.Sim

Simulation reinvented

SOMATOM go.Sim can increase workforce productivity and optimise clinical operations. It helps you get the full picture faster so you can spend less time managing CT simulation and more time focusing on patients.


SOMATOM go.Open Pro

The future is in motion

SOMATOM go.Open Pro helps you expand precision medicine and make individualised therapy available to more patients. This is an advanced, intelligent CT simulator that helps you push the boundaries to fight the most challenging cancers.

siemens-healthineers.co.uk/radiotherapy





The more efficient, flexible, personal **& intelligent way to outsmart cancer.**

With Ethos[™] therapy, you can adapt treatment plans daily while transforming your cancer fight completely.

Ethos therapy is our Al-driven holistic solution that lets you choose the most appropriate treatment option based on daily changes in patient anatomy. It also delivers an entire adaptive treatment in a typical 15-minute timeslot, from setup through delivery. Redefine how you fight cancer—experience Ethos therapy at varian.com/ethos today.

Safety Information: Radiation may cause side effects and may not be appropriate for all cancers. © 2020 Varian Medical Systems, Inc. Varian is a registered trademark of Varian Medical Systems, Inc.

varian





To find out more visit our website <u>https://xiel.co.uk</u> or call 01749 372217 or email <u>info@xiel.co.uk</u>

Wednesday 24 March

Strategy / Policy / Workforce		
Radiotherapy errors and near misses – learning opportunities		
13:00	Welcome and introduction	
Session: Strategy / Policy / Workforce and education		
13:20	The All Party Parliamentary Group for Radiotherapy (APPG-RT) Dr Patricia Price, Visiting Professor, Imperial College London	
13:50	Medical workforce issues in oncology Ms Julie Massey, Head of Radiation Services, The Clatterbridge Cancer Centre NHS Foundation Trust	
14:20	Break / ePoster viewing / Meet the sponsors	
Session: Radiotherapy errors and near misses – learning opportunities		
14:50	National learning opportunities from the RTE Ms Helen Best, Senior Clinical Radiotherapy Officer, Medical Exposures Group, Public Health England	
15:20	Learning opportunities from local and national RTE Ms Oonagh Maguire and Una McElroy, Quality Assurance Therapeutic Radiographers, Belfast Health and Social Care Trust	
15:50	Using local radiotherapy error analysis to inform training packages Ms Alison Sanneh, Principal Educator – Radiotherapy, The Christie NHS Foundation Trust; and Ms Julie Davies, Lead Radiographer, The Christie at Oldham	

16:20 Close of day

Thursday 25 March

Proffered presentations		
13:00	Welcome and introduction	
13:05	Assessment of automated radiotherapy plan generation for bladder cancer using the Ethos TPS Dr Matthew Bolt, Radiotherapy Physicist, Royal Surrey NHS Foundation Trust	
13:35	Assessing the impact of COVID-19 on head and neck cancer treatment and preparing for the	
13.35	next wave	
	Mr Karan Daga, Medical Student, University of Manchester	
14:05	Hypofractionated radiotherapy as a definitive treatment for Basal Cell Carcinoma: A single institution experience	
	Dr Shahid Gilani, Doctor, University Hospitals of North Midlands NHS Trust	
44.25		
14:35	Break / ePoster viewing / Meet the sponsors	
15:05	A feasibility study of Velocity deformable image registration of planning CT to cone-beam CT for adaptive proton treatment planning of head and neck cancer Ms Virginia Marin Anaya, Proton Therapy Physicist, University College London Hospitals NHS Foundation Trust	
15:35	IPEM Guidance on the use of MRI for external beam radiotherapy treatment planning Dr Richard Speight, Principal Clinical Scientist ARTNET, St James University Hospital	
16:05	18F-FDG PET-CT incidental lung findings in asymptomatic confirmed and suspected COVID-19 patients during the pandemic peak Ms Alice Bonanomi, Radiology Resident, Papa Giovanni XXIII Hospital, Bergamo	

16:35 Close of day

Friday 26 March


Hypofractionation and clinical trials		
13:00	Welcome and introduction	
13:05	Applied radiobiology in radiosurgical techniques, shorter fractionation schedules and proton therapy	
42.25	Professor Bleddyn Jones, Professor of Clinical Radiation Biology, University of Oxford	
13:35	Clinical update – FAST and FAST-forward trials Dr Duncan Wheatley, Consultant Clinical Oncologist Royal Cornwall Hospital and Director of Research and Innovation Cornwall	
14:05	Break / ePoster viewing / Meet the sponsors	
14:35	Clinical trials of novel radiotherapy-drug combinations Professor Anthony Chalmers, Chair of Clinical Oncology (Clinical Trials Research), University of Glasgow	
15:05	Close of event	



PIONEERING SAAS OPTIMISING RADIOTHERAPY TREATMENT PLANNING WITH AI

Our AI-powered Segmentation Service helps to standardise and automate contouring to streamline workflow in radiotherapy. The GDPR compliant deep learning model produces consistent contouring in minutes while maintaining **the highest standards of quality for every patient, every time.**





MVision's CE marked automatic segmentation modules cover all major cancer sites as well as **lymph nodes**.

FIND OUT MORE

Visit <u>www.mvision.ai</u> or contact us at **info@mvision.ai** SRS/SBRT SGRT Varian Halcyon™ Elekta Unity

One Phantom. All Tasks.

SYSTEM QA LINAC QA PATIENT QA



RUBY The New Modular QA Phantom

PTWRUBY

- Comprehensive testing of the entire treatment chain with one single phantom
- Complete end-to-end tests with one single insert
- Verification of CT/MRI image registration

System alignment checks, including 6D couch QA

1:

- Automated Winston Lutz testing with IsoCheck^{epid}
- Patient plan verification, including non-coplanar treatments, with film and detector



PTWRUBY

Developing solutions that aid adherence is in our blood



New Imatinib 80mg/ml Oral Solution

Easier to take, easier to titrate



Abbreviated Prescribing Information: Imatinib 80 mg/ml Oral solution. Consult Summary of Product Characteristics before prescribing. Presentation: A dear yellow to brownish yellow coloured solution with characteristic doru filled in amber colour PEI bellow with a child-resistant transpeevident core, containing 80 mg intraiting. I ml (as messilte). Therapeutic Indications: Adult and poetitic patients with newly diagnosed Philodelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Adult and poetiatic patients with newly diagnosed Philodelphia transmose and positive curle lympholostic leukaemia (Ph-ALL) integrated with chemotherapy. Adult patients with newly diagnosed Philodelphia transmose messitic. Therapeutic adult and poetiatic patients with newly diagnosed Philodelphia (HES) md/or chronic eosinaphilic leukaemia (EL) with PILIPDGFR gene rearrangements. Adult patients with advanced hyperosinaphilic leukaemia (HES) and/or chronic eosinaphilic leukaemia (EL) with PILIPDGFR rearrangement. The treatment of adult patients with unersectable dermatofibrosorcomo protuberars. (DFSP) and adult patients with necurent and/or metastratic DFSP who are not eligible for surgery. Posology and Method of Administration: Theory should be initiated by a physician experienced in the treatment of patients with heemstopical malignancies and malignant surcomas. CML in adult patients: 400 mg/day for adult patients: in chronic phose. Bec nosilidation and maintennone phases of elomotherapy to radult patients: 300 mg/day is combinedrapy in the induction phase, the consolidation and maintennone phases of elomotherapy tor adult patients with Newl diagnosed Ph+ALL. The duration of the therapy can vary. MDS/MPD: 400 mg/day for adult patients with MDS/MPD. HES/CEL. The ecommended dose recommended in charged circumstances. Thein tissffciency: Chrients with NetS/MPD. HES/CEL the commended dose recommended in the Heavier and t

cution. Gose monitoring of growth in children under imntinib treatment is recommended. **Fertility, Pregnancy and Lactation**: Women of childbearing potential must be advised to use effective contraception during treatment. Imntinib should not be used during pregnancy unless, clearly necessary. Women taking inactinises, **Undesirable Effects**: *Very camman*: Neutopenia, thrombocytopenia, nonsenia, nausea, diarrhoea, vorning, dyspepsia, periotrital oedema, derantitis, *eczema frash,* muscle spasm and carmary, neusculoskeletal pain including myalqia, arthridiga, bone pain, fluid reletation on deedema, fortigue, weight increased. *Camman*: Poworkpone, fieldle neutropenia, nonexia, instrumin, dzziness, poresthesia, toste disturbance, hypoaesthesia, eyelid oedema, a termination, inditatens, gastro-esephageal relfux, constipation, dy mouth, gastrais, instead isturbance, hypoaesthesia, eyelid oedema, dy kine researd. *Camman*: Poworkpone, fieldle neutropenia, nonexia, instrumi, dzziness, poresin, mosarca, chills, rigors, weight decrease. *Uncamman*: Herpes zoster, herpes simplex, nasopharyngitis, pneumonia, sinusitis, cellultis, upper respiratory tract infection, influenza, uninary tract infection, gastroententis, sepsis, thrombocytheamia, lympfhapenia, bane marrow depression, essionphila, lymphadenopathy, hypokalaemia, hyposhaemia, orgenada peptite, lehytoriton, gastroententis, herpericure, hypoerytocamia, hyporetarion, active searce appetite, elytophosphane, neuropathy, memory hypertension, horaving searce and searce, priseria, carefuel hearonthage, eqe initiator, eye pain, othila oedema, sectle alternative, menorhage, heptensis, nacular oedema, vertigo, tinnitus, heaning lass, polititions, tarkycardia, cardia cfulure, congestive pulmonory oedema, hypertension, heamatoma, subdura heamatomes, heamatoma, subdura heamatoma, entripo, ereit heamatoma, server y nacread, garneceantis, hyperelinichane, heamatoris,

Rosemont

Rosemont Pharmaceuticals Ltd. Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LSII 9XE T +44 (0)113 244 1400 F +44 (0)113 245 3567 E infodesk@rosemontpharma.com Sales/Customer Service: T +44 (0)113 244 1999 F +44 (0)113 246 0738 W www.rosemontpharma.com

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Rosemont Pharmaceuticals Ltd on 0113 244 1400

HE HE HOLMIUM PLATFORM



Three integrated products **DELIVERING INDIVIDUALIZED SIRT** at its full potential



All brand names are trademarks or registered trademarks of Quirem Medical B.V., a Terumo group company. Clinical images courtesy of University Medical Center Utrecht, the Netherlands. Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. Not all products are cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.







With sincere thanks to our platinum sponsors





f /britishinstituteofradiology

in The British Institute of Radiology

48–50 St John Street, London, EC1M 4DG www.bir.org.uk

Registered charity number: 215869